Financial & Business News
LATEST INVESTING HEADLINES
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Affirm Holdings, Inc. ("Affirm" or the "Company") (NASDAQ: AFRM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH).
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc. ("HealthEquity" or the "Company") (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Newsmax stock surged unrealistically post-IPO, but now trades at a more reasonable $23. Affiliate fees and digital subscriptions both saw sharp increases in 2024, suggesting the potential for revenue growth and margin improvement, allowing the business to grow into a currently high valuation. But 2024 looks like an outlier, with a 26% increase in revenue driven largely by those new launches.
Palantir Technologies ( PLTR ) delivered strong Q1 2025 results, with revenue rising 39% year-over-year to $884 million and adjusted EPS meeting expectations at $0.13. The company raised its full-year guidance, projecting revenue between $3.89 billion and $3.90 billion, surpassing analyst estimates.
TAMPA, Fla. , May 6, 2025 /PRNewswire/ -- Heritage Insurance Holdings, Inc. (NYSE: HRTG) ("Heritage" or the "Company"), a super-regional property and casualty insurance holding company, today reported first quarter of 2025 financial results.
BOCA RATON, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (the "Company") (Nasdaq: NEWT) reports its financial and operating results for the three months ended March 31, 2025 ("1Q25").
N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity. eXoZymes used its AI-driven development platform to progress from idea to purpose-built subsidiary in less than 3 months and at a fraction of normal SynBio R&D cost.
NEWARK, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Artesian Resources Corporation (Nasdaq: ARTNA) announces today that its Board of Directors has approved a 2% increase in the quarterly dividend per share on the company's Class A and Class B Common Stock, raising the annualized dividend to $1.2296 per share. The quarterly dividend rate of $0.3074 per share is payable May 27, 2025 to shareholders of record at the close of business on May 16, 2025.